ANDA 211207, held by Chartwell Rx. Clobetasol Propionate.
As of Nov 15, 2026, ANDA 211207 (Clobetasol Propionate), held by Chartwell Rx, was first approved by FDA on Mar 26, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 26, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clobetasol Propionate0.05% ยท cream;topical | Clobetasol Propionate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
